M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera PharmaphorumJazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaphorum Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls shortNext: uniQure sets course to US filing for Huntington gene therapy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
